InnovaHealth Partners Invests in Koelis, a Leader in Prostate Cancer Diagnostics and Treatment

NEW YORK, Sept. 17, 2019 (GLOBE NEWSWIRE) — Koelis SAS ("Koelis" or the "Company") and InnovaHealth Partners, LP ("InnovaHealth") jointly announced today along with Medevice Partners ("Medevice") that InnovaHealth has made a growth equity investment in Koelis and acquired a majority interest in the Company.

Koelis is a leadership innovator in the market for image–guided systems for prostate cancer diagnosis and treatment. The Company's products have regulatory clearances and have been commercialized in the US, Europe, and most Asian markets. The Koelis Trinity System offers market–leading features including "fusion" imaging, organ tracking, robotic assistance, and focal therapy. The Koelis system is an important new technology that enables urologists to more accurately diagnose prostate cancer and can offer patients less invasive, non–radical treatment choices. The Company is based in Grenoble, France and Boston, Massachusetts, USA, and has an office in Hong Kong.

Antoine Leroy, Koelis Chief Executive Officer, said, "We are very excited to be partnering with InnovaHealth, whose specialization in medical devices will substantially increase the value of our Company. InnovaHealth is the ideal partner to support our Company's global business growth given their proven track record of value creation within their portfolio. Their strategic relationships, global clinician network and capital will be instrumental in the years ahead."

Ccile Real, Medevice President & CEO, added, "As both a close operational and financial partner of Koelis since 2012, we share Antoine's excitement and welcome the InnovaHealth team as we all embark on the next phase of the Company's growth and value creation."

Mortimer "Tim" Berkowitz III, InnovaHealth President & CEO, said, "In transforming the way prostate cancer is diagnosed and treated, we see enormous potential to bring Koelis' differentiated technology to scale in a $2.5 billion global market where it addresses significant unmet clinical needs." U.S. based InnovaHealth is the leading specialist medical device growth private equity firm. The InnovaHealth team manages approximately $200 million and has over 100 years of experience investing in the global medical device market.

Digital Reasoning Announces Strategic Investment from SC Ventures Accelerating Global Expansion of AI Solutions for Communications Surveillance in New Geographies

NASHVILLE, Tenn., Sept. 17, 2019 (GLOBE NEWSWIRE) — Digital Reasoning, a leader in Artificial Intelligence (AI) that understands human intentions and behaviors, today announced a strategic investment from SC Ventures, the innovation, ventures and fintech investments unit of Standard Chartered Bank, bringing its Series D–1 funding round total to $40 million. In addition to this investment, Digital Reasoning will partner with Standard Chartered Bank to expand its financial services product offerings in Communications Surveillance across Asia Pacific, the Middle East, and other international markets.

"Digital Reasoning is the leader in communications analytics, identifying and finding key risks and insights from human language and behavior. Doing this requires an increased understanding of diverse languages and contexts across numerous cultures," said Tim Estes, Founder and President of Digital Reasoning. "Standard Chartered is a leading global bank with a very diverse footprint. Through the partnership, we believe we can accelerate our solutions' applicability across Asia, the Middle East, and Africa. Together we will further democratize using AI to understand the languages in markets where these new solutions can be used for good."

The investment from SC Ventures will enable Digital Reasoning to continue its market leadership position in e–communications and Voice Surveillance for Compliance, as well as expand into other adjacent use cases within financial institutions globally. Additionally, it will support Digital Reasoning's efforts to broaden its pre–trained model catalog to support growth in financial markets across Asia, the Middle East, and Africa.

Alex Manson, Global Head of SC Ventures, said: "Fighting misconduct and unethical behavior in financial services is a non–negotiable commitment as a bank, a task rendered even more complex by our digitally connected financial system. Digital Reasoning is a leader in Conduct Surveillance and well–positioned to help our industry fulfill that commitment."

Digital Reasoning's Series D–1 funding round had a first close last year, led by BNP Paribas with participation from Barclays, Square Capital, Goldman Sachs, Nasdaq, Lemhi Ventures, HCA, and the Partnership Fund for New York City. Macquarie subsequently invested in this funding round, with SC Ventures now being the latest investor to contribute.

Media Contact
Randi Schochet | randi.schochet@digitalreasoning.com | +1 212–402–6113

About Digital Reasoning
Digital Reasoning is a global leader in Artificial Intelligence that understands human intentions and behaviors. Our award–winning AI platform automates key tasks and uncovers transformative insights across vast amounts of human communications for many of the world's leading financial services and healthcare organizations. For more information go to www.digitalreasoning.com and follow on Twitter at @dreasoning.

About SC Ventures

SC Ventures is Standard Chartered Bank's innovation, fintech investment and ventures unit. Focused on "rewiring the DNA in banking", SC Ventures aims to develop an innovation culture and mindset, deepen capabilities and experiment with new business models through an open platform and network of people and partnerships. It runs an eXellerator innovation lab network across Singapore, Shanghai, Hong Kong, London, Nairobi, and San Francisco.
For more information, please visit: http://scventures.io/